In murine tumor models with high PD1+ T cells, CD40 agonism reversed T cell exhaustion and enhanced response to anti-PD-1 and anti-CTLA-4 immune checkpoint inhibition, suggesting a re-sensitization benefit for patients who experience resistance to ICI [159]. Here, CTLA4 is linked to neoplasm.